UK markets open in 6 hours 20 minutes
  • NIKKEI 225

    28,809.22
    +300.67 (+1.05%)
     
  • HANG SENG

    28,621.92
    -513.81 (-1.76%)
     
  • CRUDE OIL

    61.17
    -0.18 (-0.29%)
     
  • GOLD FUTURES

    1,793.70
    +0.60 (+0.03%)
     
  • DOW

    34,137.31
    +316.01 (+0.93%)
     
  • BTC-GBP

    38,816.37
    -1,883.61 (-4.63%)
     
  • CMC Crypto 200

    1,245.67
    -17.30 (-1.37%)
     
  • ^IXIC

    13,950.22
    +163.95 (+1.19%)
     
  • ^FTAS

    3,935.64
    +15.59 (+0.40%)
     

Legionella Testing Market to Reach $421.9 Million by 2027

ReportLinker
·27-min read

Project Details: - StrategyR - A Trademark of Global Industry Analysts, Inc. - Project Edition: 7. - Influencer Pool: 2926. - MarketGlass™ Platform - Our influencer driven interactive research platform draws from unique perspectives of participating executives from featured companies.

New York, April 01, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Legionella Testing Industry" - https://www.reportlinker.com/p05961012/?utm_source=GNW
In addition to being a global intelligence exchange platform, MarketGlass™ is a powerful knowledge center that delivers dynamic project-focused market intelligence. Client companies will have complete insider access to the project Data stack.
- Interactive peer-to-peer and enterprise-to-enterprise ideation and market intelligence exchange is facilitated via a robust, secure, and validated process. The process draws from uniquely qualified project-specific and geographically focused executives overseeing business development, marketing and sales operations.

  • Trends & Factors - Identifying and validating local trends and factors driving each competitive marketplace. These factors include pricing variances, market trajectories, Covid-19 impact and recovery, locally active leading brands, and other parameters impacting the region in the short to medium term such as supply chain realignments.

  • Mobile Access & App - Our mobile version of the report may be accessed via our mobile app or directly for a full mobile experience.

  • Complimentary Updates - for one year. At least one update in 12-month period is normal and anytime there’s a significant change affecting the market dynamics.

  • Bespoke Updates & Team Collaborations - Clients may build a bespoke version of our report with peers on our MarketGlass™ platform which enables multidimensional data simulations.

  • Knowledge Center - clients have full-stack data access for project data they support or purchase including primary research engagement stats, companies and executives.

Abstract:
- Global Legionella Testing Market to Reach $421.9 Million by 2027
- Amid the COVID-19 crisis, the global market for Legionella Testing estimated at US$244.5 Million in the year 2020, is projected to reach a revised size of US$421.9 Million by 2027, growing at a CAGR of 8.1% over the analysis period 2020-2027. Culture Methods, one of the segments analyzed in the report, is projected to record a 8.4% CAGR and reach US$93 Million by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Urinary Antigen Test (UAT) segment is readjusted to a revised 8.4% CAGR for the next 7-year period.
- The U.S. Market is Estimated at $66.1 Million, While China is Forecast to Grow at 12.3% CAGR
- The Legionella Testing market in the U.S. is estimated at US$66.1 Million in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$95.7 Million by the year 2027 trailing a CAGR of 12.2% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 4.4% and 7.2% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 5.3% CAGR.
- Serology Segment to Record 7.1% CAGR
- In the global Serology segment, USA, Canada, Japan, China and Europe will drive the 6.6% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$14.6 Million in the year 2020 will reach a projected size of US$22.7 Million by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$58.6 Million by the year 2027, while Latin America will expand at a 8.4% CAGR through the analysis period.

- Select Competitors (Total 41 Featured) -

  • Alere, Inc.

  • Aquacert Ltd

  • Beckman Coulter, Inc.

  • Becton, Dickinson and Company (BD)

  • BioMérieux SA

  • Bio-Rad Laboratories, Inc.

  • Eiken Chemical Co., Ltd.

  • Hologic, Inc.

  • Idexx Laboratories Inc.

  • Roche Diagnostics

  • Thermo Fischer Scientific, Inc.




Read the full report: https://www.reportlinker.com/p05961012/?utm_source=GNW

I. METHODOLOGY

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW
Influencer Market Insights
World Market Trajectories
Impact of Covid-19 and a Looming Global Recession

2. FOCUS ON SELECT PLAYERS

3. MARKET TRENDS & DRIVERS

4. GLOBAL MARKET PERSPECTIVE
Table 1: World Current & Future Analysis for Legionella Testing
by Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2020 through 2027 and % CAGR

Table 2: World Historic Review for Legionella Testing by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2012 through 2019 and % CAGR

Table 3: World 15-Year Perspective for Legionella Testing by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa Markets for Years 2012, 2020 & 2027

Table 4: World Current & Future Analysis for Culture Methods by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2020 through 2027 and % CAGR

Table 5: World Historic Review for Culture Methods by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2012 through 2019 and % CAGR

Table 6: World 15-Year Perspective for Culture Methods by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2020 & 2027

Table 7: World Current & Future Analysis for Urinary Antigen
Test (UAT) by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Thousand
for Years 2020 through 2027 and % CAGR

Table 8: World Historic Review for Urinary Antigen Test (UAT)
by Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2012 through 2019 and % CAGR

Table 9: World 15-Year Perspective for Urinary Antigen Test
(UAT) by Geographic Region - Percentage Breakdown of Value
Sales for USA, Canada, Japan, China, Europe, Asia-Pacific,
Latin America, Middle East and Africa for Years 2012, 2020 &
2027

Table 10: World Current & Future Analysis for Serology by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2020 through 2027 and % CAGR

Table 11: World Historic Review for Serology by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2012 through 2019 and
% CAGR

Table 12: World 15-Year Perspective for Serology by Geographic
Region - Percentage Breakdown of Value Sales for USA, Canada,
Japan, China, Europe, Asia-Pacific, Latin America, Middle East
and Africa for Years 2012, 2020 & 2027

Table 13: World Current & Future Analysis for Direct
Fluorescence Antibody Test (DFA) by Geographic Region - USA,
Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa Markets - Independent Analysis of Annual
Sales in US$ Thousand for Years 2020 through 2027 and % CAGR

Table 14: World Historic Review for Direct Fluorescence
Antibody Test (DFA) by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific, Latin America, Middle East and
Africa Markets - Independent Analysis of Annual Sales in US$
Thousand for Years 2012 through 2019 and % CAGR

Table 15: World 15-Year Perspective for Direct Fluorescence
Antibody Test (DFA) by Geographic Region - Percentage Breakdown
of Value Sales for USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa for Years
2012, 2020 & 2027

Table 16: World Current & Future Analysis for Nucleic
Acid-based Detection by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific, Latin America, Middle East and
Africa Markets - Independent Analysis of Annual Sales in US$
Thousand for Years 2020 through 2027 and % CAGR

Table 17: World Historic Review for Nucleic Acid-based
Detection by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Thousand
for Years 2012 through 2019 and % CAGR

Table 18: World 15-Year Perspective for Nucleic Acid-based
Detection by Geographic Region - Percentage Breakdown of Value
Sales for USA, Canada, Japan, China, Europe, Asia-Pacific,
Latin America, Middle East and Africa for Years 2012, 2020 &
2027

Table 19: World Current & Future Analysis for Clinical Testing
Methods by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Thousand
for Years 2020 through 2027 and % CAGR

Table 20: World Historic Review for Clinical Testing Methods by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2012 through 2019 and % CAGR

Table 21: World 15-Year Perspective for Clinical Testing
Methods by Geographic Region - Percentage Breakdown of Value
Sales for USA, Canada, Japan, China, Europe, Asia-Pacific,
Latin America, Middle East and Africa for Years 2012, 2020 &
2027

Table 22: World Current & Future Analysis for Environmental
Testing Methods by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific, Latin America, Middle East and
Africa Markets - Independent Analysis of Annual Sales in US$
Thousand for Years 2020 through 2027 and % CAGR

Table 23: World Historic Review for Environmental Testing
Methods by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Thousand
for Years 2012 through 2019 and % CAGR

Table 24: World 15-Year Perspective for Environmental Testing
Methods by Geographic Region - Percentage Breakdown of Value
Sales for USA, Canada, Japan, China, Europe, Asia-Pacific,
Latin America, Middle East and Africa for Years 2012, 2020 &
2027

Table 25: World Current & Future Analysis for Hospitals by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2020 through 2027 and % CAGR

Table 26: World Historic Review for Hospitals by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2012 through 2019 and
% CAGR

Table 27: World 15-Year Perspective for Hospitals by Geographic
Region - Percentage Breakdown of Value Sales for USA, Canada,
Japan, China, Europe, Asia-Pacific, Latin America, Middle East
and Africa for Years 2012, 2020 & 2027

Table 28: World Current & Future Analysis for Diagnostic
Laboratories by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Thousand
for Years 2020 through 2027 and % CAGR

Table 29: World Historic Review for Diagnostic Laboratories by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2012 through 2019 and % CAGR

Table 30: World 15-Year Perspective for Diagnostic Laboratories
by Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2020 & 2027

Table 31: World Current & Future Analysis for Clinics by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2020 through 2027 and % CAGR

Table 32: World Historic Review for Clinics by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2012 through 2019 and
% CAGR

Table 33: World 15-Year Perspective for Clinics by Geographic
Region - Percentage Breakdown of Value Sales for USA, Canada,
Japan, China, Europe, Asia-Pacific, Latin America, Middle East
and Africa for Years 2012, 2020 & 2027

Table 34: World Current & Future Analysis for Other End-Uses by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2020 through 2027 and % CAGR

Table 35: World Historic Review for Other End-Uses by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2012 through 2019 and % CAGR

Table 36: World 15-Year Perspective for Other End-Uses by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2020 & 2027

III. MARKET ANALYSIS

UNITED STATES
Table 37: USA Current & Future Analysis for Legionella Testing
by Test Type - Culture Methods, Urinary Antigen Test (UAT),
Serology, Direct Fluorescence Antibody Test (DFA) and Nucleic
Acid-based Detection - Independent Analysis of Annual Sales in
US$ Thousand for the Years 2020 through 2027 and % CAGR

Table 38: USA Historic Review for Legionella Testing by Test
Type - Culture Methods, Urinary Antigen Test (UAT), Serology,
Direct Fluorescence Antibody Test (DFA) and Nucleic Acid-based
Detection Markets - Independent Analysis of Annual Sales in US$
Thousand for Years 2012 through 2019 and % CAGR

Table 39: USA 15-Year Perspective for Legionella Testing by
Test Type - Percentage Breakdown of Value Sales for Culture
Methods, Urinary Antigen Test (UAT), Serology, Direct
Fluorescence Antibody Test (DFA) and Nucleic Acid-based
Detection for the Years 2012, 2020 & 2027

Table 40: USA Current & Future Analysis for Legionella Testing
by Application - Clinical Testing Methods and Environmental
Testing Methods - Independent Analysis of Annual Sales in US$
Thousand for the Years 2020 through 2027 and % CAGR

Table 41: USA Historic Review for Legionella Testing by
Application - Clinical Testing Methods and Environmental
Testing Methods Markets - Independent Analysis of Annual Sales
in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 42: USA 15-Year Perspective for Legionella Testing by
Application - Percentage Breakdown of Value Sales for Clinical
Testing Methods and Environmental Testing Methods for the Years
2012, 2020 & 2027

Table 43: USA Current & Future Analysis for Legionella Testing
by End-Use - Hospitals, Diagnostic Laboratories, Clinics and
Other End-Uses - Independent Analysis of Annual Sales in US$
Thousand for the Years 2020 through 2027 and % CAGR

Table 44: USA Historic Review for Legionella Testing by End-Use -
Hospitals, Diagnostic Laboratories, Clinics and Other
End-Uses Markets - Independent Analysis of Annual Sales in US$
Thousand for Years 2012 through 2019 and % CAGR

Table 45: USA 15-Year Perspective for Legionella Testing by
End-Use - Percentage Breakdown of Value Sales for Hospitals,
Diagnostic Laboratories, Clinics and Other End-Uses for the
Years 2012, 2020 & 2027

CANADA
Table 46: Canada Current & Future Analysis for Legionella
Testing by Test Type - Culture Methods, Urinary Antigen Test
(UAT), Serology, Direct Fluorescence Antibody Test (DFA) and
Nucleic Acid-based Detection - Independent Analysis of Annual
Sales in US$ Thousand for the Years 2020 through 2027 and %
CAGR

Table 47: Canada Historic Review for Legionella Testing by Test
Type - Culture Methods, Urinary Antigen Test (UAT), Serology,
Direct Fluorescence Antibody Test (DFA) and Nucleic Acid-based
Detection Markets - Independent Analysis of Annual Sales in US$
Thousand for Years 2012 through 2019 and % CAGR

Table 48: Canada 15-Year Perspective for Legionella Testing by
Test Type - Percentage Breakdown of Value Sales for Culture
Methods, Urinary Antigen Test (UAT), Serology, Direct
Fluorescence Antibody Test (DFA) and Nucleic Acid-based
Detection for the Years 2012, 2020 & 2027

Table 49: Canada Current & Future Analysis for Legionella
Testing by Application - Clinical Testing Methods and
Environmental Testing Methods - Independent Analysis of Annual
Sales in US$ Thousand for the Years 2020 through 2027 and %
CAGR

Table 50: Canada Historic Review for Legionella Testing by
Application - Clinical Testing Methods and Environmental
Testing Methods Markets - Independent Analysis of Annual Sales
in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 51: Canada 15-Year Perspective for Legionella Testing by
Application - Percentage Breakdown of Value Sales for Clinical
Testing Methods and Environmental Testing Methods for the Years
2012, 2020 & 2027

Table 52: Canada Current & Future Analysis for Legionella
Testing by End-Use - Hospitals, Diagnostic Laboratories,
Clinics and Other End-Uses - Independent Analysis of Annual
Sales in US$ Thousand for the Years 2020 through 2027 and %
CAGR

Table 53: Canada Historic Review for Legionella Testing by
End-Use - Hospitals, Diagnostic Laboratories, Clinics and Other
End-Uses Markets - Independent Analysis of Annual Sales in US$
Thousand for Years 2012 through 2019 and % CAGR

Table 54: Canada 15-Year Perspective for Legionella Testing by
End-Use - Percentage Breakdown of Value Sales for Hospitals,
Diagnostic Laboratories, Clinics and Other End-Uses for the
Years 2012, 2020 & 2027

JAPAN
Table 55: Japan Current & Future Analysis for Legionella
Testing by Test Type - Culture Methods, Urinary Antigen Test
(UAT), Serology, Direct Fluorescence Antibody Test (DFA) and
Nucleic Acid-based Detection - Independent Analysis of Annual
Sales in US$ Thousand for the Years 2020 through 2027 and %
CAGR

Table 56: Japan Historic Review for Legionella Testing by Test
Type - Culture Methods, Urinary Antigen Test (UAT), Serology,
Direct Fluorescence Antibody Test (DFA) and Nucleic Acid-based
Detection Markets - Independent Analysis of Annual Sales in US$
Thousand for Years 2012 through 2019 and % CAGR

Table 57: Japan 15-Year Perspective for Legionella Testing by
Test Type - Percentage Breakdown of Value Sales for Culture
Methods, Urinary Antigen Test (UAT), Serology, Direct
Fluorescence Antibody Test (DFA) and Nucleic Acid-based
Detection for the Years 2012, 2020 & 2027

Table 58: Japan Current & Future Analysis for Legionella
Testing by Application - Clinical Testing Methods and
Environmental Testing Methods - Independent Analysis of Annual
Sales in US$ Thousand for the Years 2020 through 2027 and %
CAGR

Table 59: Japan Historic Review for Legionella Testing by
Application - Clinical Testing Methods and Environmental
Testing Methods Markets - Independent Analysis of Annual Sales
in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 60: Japan 15-Year Perspective for Legionella Testing by
Application - Percentage Breakdown of Value Sales for Clinical
Testing Methods and Environmental Testing Methods for the Years
2012, 2020 & 2027

Table 61: Japan Current & Future Analysis for Legionella
Testing by End-Use - Hospitals, Diagnostic Laboratories,
Clinics and Other End-Uses - Independent Analysis of Annual
Sales in US$ Thousand for the Years 2020 through 2027 and %
CAGR

Table 62: Japan Historic Review for Legionella Testing by
End-Use - Hospitals, Diagnostic Laboratories, Clinics and Other
End-Uses Markets - Independent Analysis of Annual Sales in US$
Thousand for Years 2012 through 2019 and % CAGR

Table 63: Japan 15-Year Perspective for Legionella Testing by
End-Use - Percentage Breakdown of Value Sales for Hospitals,
Diagnostic Laboratories, Clinics and Other End-Uses for the
Years 2012, 2020 & 2027

CHINA
Table 64: China Current & Future Analysis for Legionella
Testing by Test Type - Culture Methods, Urinary Antigen Test
(UAT), Serology, Direct Fluorescence Antibody Test (DFA) and
Nucleic Acid-based Detection - Independent Analysis of Annual
Sales in US$ Thousand for the Years 2020 through 2027 and %
CAGR

Table 65: China Historic Review for Legionella Testing by Test
Type - Culture Methods, Urinary Antigen Test (UAT), Serology,
Direct Fluorescence Antibody Test (DFA) and Nucleic Acid-based
Detection Markets - Independent Analysis of Annual Sales in US$
Thousand for Years 2012 through 2019 and % CAGR

Table 66: China 15-Year Perspective for Legionella Testing by
Test Type - Percentage Breakdown of Value Sales for Culture
Methods, Urinary Antigen Test (UAT), Serology, Direct
Fluorescence Antibody Test (DFA) and Nucleic Acid-based
Detection for the Years 2012, 2020 & 2027

Table 67: China Current & Future Analysis for Legionella
Testing by Application - Clinical Testing Methods and
Environmental Testing Methods - Independent Analysis of Annual
Sales in US$ Thousand for the Years 2020 through 2027 and %
CAGR

Table 68: China Historic Review for Legionella Testing by
Application - Clinical Testing Methods and Environmental
Testing Methods Markets - Independent Analysis of Annual Sales
in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 69: China 15-Year Perspective for Legionella Testing by
Application - Percentage Breakdown of Value Sales for Clinical
Testing Methods and Environmental Testing Methods for the Years
2012, 2020 & 2027

Table 70: China Current & Future Analysis for Legionella
Testing by End-Use - Hospitals, Diagnostic Laboratories,
Clinics and Other End-Uses - Independent Analysis of Annual
Sales in US$ Thousand for the Years 2020 through 2027 and %
CAGR

Table 71: China Historic Review for Legionella Testing by
End-Use - Hospitals, Diagnostic Laboratories, Clinics and Other
End-Uses Markets - Independent Analysis of Annual Sales in US$
Thousand for Years 2012 through 2019 and % CAGR

Table 72: China 15-Year Perspective for Legionella Testing by
End-Use - Percentage Breakdown of Value Sales for Hospitals,
Diagnostic Laboratories, Clinics and Other End-Uses for the
Years 2012, 2020 & 2027

EUROPE
Table 73: Europe Current & Future Analysis for Legionella
Testing by Geographic Region - France, Germany, Italy, UK,
Spain, Russia and Rest of Europe Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2020 through 2027 and
% CAGR

Table 74: Europe Historic Review for Legionella Testing by
Geographic Region - France, Germany, Italy, UK, Spain, Russia
and Rest of Europe Markets - Independent Analysis of Annual
Sales in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 75: Europe 15-Year Perspective for Legionella Testing by
Geographic Region - Percentage Breakdown of Value Sales for
France, Germany, Italy, UK, Spain, Russia and Rest of Europe
Markets for Years 2012, 2020 & 2027

Table 76: Europe Current & Future Analysis for Legionella
Testing by Test Type - Culture Methods, Urinary Antigen Test
(UAT), Serology, Direct Fluorescence Antibody Test (DFA) and
Nucleic Acid-based Detection - Independent Analysis of Annual
Sales in US$ Thousand for the Years 2020 through 2027 and %
CAGR

Table 77: Europe Historic Review for Legionella Testing by Test
Type - Culture Methods, Urinary Antigen Test (UAT), Serology,
Direct Fluorescence Antibody Test (DFA) and Nucleic Acid-based
Detection Markets - Independent Analysis of Annual Sales in US$
Thousand for Years 2012 through 2019 and % CAGR

Table 78: Europe 15-Year Perspective for Legionella Testing by
Test Type - Percentage Breakdown of Value Sales for Culture
Methods, Urinary Antigen Test (UAT), Serology, Direct
Fluorescence Antibody Test (DFA) and Nucleic Acid-based
Detection for the Years 2012, 2020 & 2027

Table 79: Europe Current & Future Analysis for Legionella
Testing by Application - Clinical Testing Methods and
Environmental Testing Methods - Independent Analysis of Annual
Sales in US$ Thousand for the Years 2020 through 2027 and %
CAGR

Table 80: Europe Historic Review for Legionella Testing by
Application - Clinical Testing Methods and Environmental
Testing Methods Markets - Independent Analysis of Annual Sales
in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 81: Europe 15-Year Perspective for Legionella Testing by
Application - Percentage Breakdown of Value Sales for Clinical
Testing Methods and Environmental Testing Methods for the Years
2012, 2020 & 2027

Table 82: Europe Current & Future Analysis for Legionella
Testing by End-Use - Hospitals, Diagnostic Laboratories,
Clinics and Other End-Uses - Independent Analysis of Annual
Sales in US$ Thousand for the Years 2020 through 2027 and %
CAGR

Table 83: Europe Historic Review for Legionella Testing by
End-Use - Hospitals, Diagnostic Laboratories, Clinics and Other
End-Uses Markets - Independent Analysis of Annual Sales in US$
Thousand for Years 2012 through 2019 and % CAGR

Table 84: Europe 15-Year Perspective for Legionella Testing by
End-Use - Percentage Breakdown of Value Sales for Hospitals,
Diagnostic Laboratories, Clinics and Other End-Uses for the
Years 2012, 2020 & 2027

FRANCE
Table 85: France Current & Future Analysis for Legionella
Testing by Test Type - Culture Methods, Urinary Antigen Test
(UAT), Serology, Direct Fluorescence Antibody Test (DFA) and
Nucleic Acid-based Detection - Independent Analysis of Annual
Sales in US$ Thousand for the Years 2020 through 2027 and %
CAGR

Table 86: France Historic Review for Legionella Testing by Test
Type - Culture Methods, Urinary Antigen Test (UAT), Serology,
Direct Fluorescence Antibody Test (DFA) and Nucleic Acid-based
Detection Markets - Independent Analysis of Annual Sales in US$
Thousand for Years 2012 through 2019 and % CAGR

Table 87: France 15-Year Perspective for Legionella Testing by
Test Type - Percentage Breakdown of Value Sales for Culture
Methods, Urinary Antigen Test (UAT), Serology, Direct
Fluorescence Antibody Test (DFA) and Nucleic Acid-based
Detection for the Years 2012, 2020 & 2027

Table 88: France Current & Future Analysis for Legionella
Testing by Application - Clinical Testing Methods and
Environmental Testing Methods - Independent Analysis of Annual
Sales in US$ Thousand for the Years 2020 through 2027 and %
CAGR

Table 89: France Historic Review for Legionella Testing by
Application - Clinical Testing Methods and Environmental
Testing Methods Markets - Independent Analysis of Annual Sales
in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 90: France 15-Year Perspective for Legionella Testing by
Application - Percentage Breakdown of Value Sales for Clinical
Testing Methods and Environmental Testing Methods for the Years
2012, 2020 & 2027

Table 91: France Current & Future Analysis for Legionella
Testing by End-Use - Hospitals, Diagnostic Laboratories,
Clinics and Other End-Uses - Independent Analysis of Annual
Sales in US$ Thousand for the Years 2020 through 2027 and %
CAGR

Table 92: France Historic Review for Legionella Testing by
End-Use - Hospitals, Diagnostic Laboratories, Clinics and Other
End-Uses Markets - Independent Analysis of Annual Sales in US$
Thousand for Years 2012 through 2019 and % CAGR

Table 93: France 15-Year Perspective for Legionella Testing by
End-Use - Percentage Breakdown of Value Sales for Hospitals,
Diagnostic Laboratories, Clinics and Other End-Uses for the
Years 2012, 2020 & 2027

GERMANY
Table 94: Germany Current & Future Analysis for Legionella
Testing by Test Type - Culture Methods, Urinary Antigen Test
(UAT), Serology, Direct Fluorescence Antibody Test (DFA) and
Nucleic Acid-based Detection - Independent Analysis of Annual
Sales in US$ Thousand for the Years 2020 through 2027 and %
CAGR

Table 95: Germany Historic Review for Legionella Testing by
Test Type - Culture Methods, Urinary Antigen Test (UAT),
Serology, Direct Fluorescence Antibody Test (DFA) and Nucleic
Acid-based Detection Markets - Independent Analysis of Annual
Sales in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 96: Germany 15-Year Perspective for Legionella Testing by
Test Type - Percentage Breakdown of Value Sales for Culture
Methods, Urinary Antigen Test (UAT), Serology, Direct
Fluorescence Antibody Test (DFA) and Nucleic Acid-based
Detection for the Years 2012, 2020 & 2027

Table 97: Germany Current & Future Analysis for Legionella
Testing by Application - Clinical Testing Methods and
Environmental Testing Methods - Independent Analysis of Annual
Sales in US$ Thousand for the Years 2020 through 2027 and %
CAGR

Table 98: Germany Historic Review for Legionella Testing by
Application - Clinical Testing Methods and Environmental
Testing Methods Markets - Independent Analysis of Annual Sales
in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 99: Germany 15-Year Perspective for Legionella Testing by
Application - Percentage Breakdown of Value Sales for Clinical
Testing Methods and Environmental Testing Methods for the Years
2012, 2020 & 2027

Table 100: Germany Current & Future Analysis for Legionella
Testing by End-Use - Hospitals, Diagnostic Laboratories,
Clinics and Other End-Uses - Independent Analysis of Annual
Sales in US$ Thousand for the Years 2020 through 2027 and %
CAGR

Table 101: Germany Historic Review for Legionella Testing by
End-Use - Hospitals, Diagnostic Laboratories, Clinics and Other
End-Uses Markets - Independent Analysis of Annual Sales in US$
Thousand for Years 2012 through 2019 and % CAGR

Table 102: Germany 15-Year Perspective for Legionella Testing
by End-Use - Percentage Breakdown of Value Sales for Hospitals,
Diagnostic Laboratories, Clinics and Other End-Uses for the
Years 2012, 2020 & 2027

ITALY
Table 103: Italy Current & Future Analysis for Legionella
Testing by Test Type - Culture Methods, Urinary Antigen Test
(UAT), Serology, Direct Fluorescence Antibody Test (DFA) and
Nucleic Acid-based Detection - Independent Analysis of Annual
Sales in US$ Thousand for the Years 2020 through 2027 and %
CAGR

Table 104: Italy Historic Review for Legionella Testing by Test
Type - Culture Methods, Urinary Antigen Test (UAT), Serology,
Direct Fluorescence Antibody Test (DFA) and Nucleic Acid-based
Detection Markets - Independent Analysis of Annual Sales in US$
Thousand for Years 2012 through 2019 and % CAGR

Table 105: Italy 15-Year Perspective for Legionella Testing by
Test Type - Percentage Breakdown of Value Sales for Culture
Methods, Urinary Antigen Test (UAT), Serology, Direct
Fluorescence Antibody Test (DFA) and Nucleic Acid-based
Detection for the Years 2012, 2020 & 2027

Table 106: Italy Current & Future Analysis for Legionella
Testing by Application - Clinical Testing Methods and
Environmental Testing Methods - Independent Analysis of Annual
Sales in US$ Thousand for the Years 2020 through 2027 and %
CAGR

Table 107: Italy Historic Review for Legionella Testing by
Application - Clinical Testing Methods and Environmental
Testing Methods Markets - Independent Analysis of Annual Sales
in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 108: Italy 15-Year Perspective for Legionella Testing by
Application - Percentage Breakdown of Value Sales for Clinical
Testing Methods and Environmental Testing Methods for the Years
2012, 2020 & 2027

Table 109: Italy Current & Future Analysis for Legionella
Testing by End-Use - Hospitals, Diagnostic Laboratories,
Clinics and Other End-Uses - Independent Analysis of Annual
Sales in US$ Thousand for the Years 2020 through 2027 and %
CAGR

Table 110: Italy Historic Review for Legionella Testing by
End-Use - Hospitals, Diagnostic Laboratories, Clinics and Other
End-Uses Markets - Independent Analysis of Annual Sales in US$
Thousand for Years 2012 through 2019 and % CAGR

Table 111: Italy 15-Year Perspective for Legionella Testing by
End-Use - Percentage Breakdown of Value Sales for Hospitals,
Diagnostic Laboratories, Clinics and Other End-Uses for the
Years 2012, 2020 & 2027

UNITED KINGDOM
Table 112: UK Current & Future Analysis for Legionella Testing
by Test Type - Culture Methods, Urinary Antigen Test (UAT),
Serology, Direct Fluorescence Antibody Test (DFA) and Nucleic
Acid-based Detection - Independent Analysis of Annual Sales in
US$ Thousand for the Years 2020 through 2027 and % CAGR

Table 113: UK Historic Review for Legionella Testing by Test
Type - Culture Methods, Urinary Antigen Test (UAT), Serology,
Direct Fluorescence Antibody Test (DFA) and Nucleic Acid-based
Detection Markets - Independent Analysis of Annual Sales in US$
Thousand for Years 2012 through 2019 and % CAGR

Table 114: UK 15-Year Perspective for Legionella Testing by
Test Type - Percentage Breakdown of Value Sales for Culture
Methods, Urinary Antigen Test (UAT), Serology, Direct
Fluorescence Antibody Test (DFA) and Nucleic Acid-based
Detection for the Years 2012, 2020 & 2027

Table 115: UK Current & Future Analysis for Legionella Testing
by Application - Clinical Testing Methods and Environmental
Testing Methods - Independent Analysis of Annual Sales in US$
Thousand for the Years 2020 through 2027 and % CAGR

Table 116: UK Historic Review for Legionella Testing by
Application - Clinical Testing Methods and Environmental
Testing Methods Markets - Independent Analysis of Annual Sales
in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 117: UK 15-Year Perspective for Legionella Testing by
Application - Percentage Breakdown of Value Sales for Clinical
Testing Methods and Environmental Testing Methods for the Years
2012, 2020 & 2027

Table 118: UK Current & Future Analysis for Legionella Testing
by End-Use - Hospitals, Diagnostic Laboratories, Clinics and
Other End-Uses - Independent Analysis of Annual Sales in US$
Thousand for the Years 2020 through 2027 and % CAGR

Table 119: UK Historic Review for Legionella Testing by End-Use -
Hospitals, Diagnostic Laboratories, Clinics and Other
End-Uses Markets - Independent Analysis of Annual Sales in US$
Thousand for Years 2012 through 2019 and % CAGR

Table 120: UK 15-Year Perspective for Legionella Testing by
End-Use - Percentage Breakdown of Value Sales for Hospitals,
Diagnostic Laboratories, Clinics and Other End-Uses for the
Years 2012, 2020 & 2027

SPAIN
Table 121: Spain Current & Future Analysis for Legionella
Testing by Test Type - Culture Methods, Urinary Antigen Test
(UAT), Serology, Direct Fluorescence Antibody Test (DFA) and
Nucleic Acid-based Detection - Independent Analysis of Annual
Sales in US$ Thousand for the Years 2020 through 2027 and %
CAGR

Table 122: Spain Historic Review for Legionella Testing by Test
Type - Culture Methods, Urinary Antigen Test (UAT), Serology,
Direct Fluorescence Antibody Test (DFA) and Nucleic Acid-based
Detection Markets - Independent Analysis of Annual Sales in US$
Thousand for Years 2012 through 2019 and % CAGR

Table 123: Spain 15-Year Perspective for Legionella Testing by
Test Type - Percentage Breakdown of Value Sales for Culture
Methods, Urinary Antigen Test (UAT), Serology, Direct

Please contact our Customer Support Center to get the complete Table of Contents
Read the full report: https://www.reportlinker.com/p05961012/?utm_source=GNW

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

CONTACT: Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001